Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I.

Mov Disord. 2012 Sep 15;27(11):1392-7. doi: 10.1002/mds.25157. Epub 2012 Sep 13.

PMID:
22976926
2.
3.

Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.

J Nucl Med. 1998 Sep;39(9):1500-8.

4.

Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.

Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW.

Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):689-95. Epub 2005 Jan 29.

PMID:
15682332
5.

Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.

Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, Erro R, Longo K, Vicidomini C, Pellecchia MT, Amboni M, Brunetti A, Salvatore M, Barone P, Pappatà S.

Parkinsonism Relat Disord. 2015 May;21(5):489-93. doi: 10.1016/j.parkreldis.2015.02.015. Epub 2015 Feb 25.

PMID:
25753457
7.

[[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.

Berding G, Brücke T, Odin P, Brooks DJ, Kolbe H, Gielow P, Harke H, Knoop BO, Dengler R, Knapp WH.

Nuklearmedizin. 2003 Feb;42(1):31-8.

PMID:
12601452
8.
9.

Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB.

J Nucl Med. 1997 Sep;38(9):1453-9.

10.
11.
12.

SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.

Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T.

J Neurol Sci. 2001 Jun 15;187(1-2):55-9.

PMID:
11440745
13.

Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.

Ichise M, Kim YJ, Erami SS, Ballinger JR, Vines D, Tanaka F, Lang AE.

J Nucl Med. 1999 Apr;40(4):530-8.

14.

Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.

Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, Wenning GK, Poewe W.

Brain. 2005 Jul;128(Pt 7):1605-12. Epub 2005 Apr 7.

15.

Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.

Kim SE, Choi JY, Choe YS, Choi Y, Lee WY.

J Nucl Med. 2003 Jun;44(6):870-6.

16.

Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.

Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, Wolters EC.

J Neurol. 1998 Jan;245(1):14-20.

PMID:
9457623
17.

Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.

Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, Videbaek C, Werdelin L.

Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1631-8. Epub 2004 Jul 22.

PMID:
15583914
18.

The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.

Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, Turk MF, Burnett OL.

Mov Disord. 1999 Nov;14(6):940-6.

PMID:
10584667
19.

[Dopamine transporter SPECT in patients with Parkinson's disease].

Hamano T, Tsuchida T, Hirayama M, Fujiyama J, Mutoh T, Yonekura Y, Kuriyama M.

Kaku Igaku. 2000 Mar;37(2):125-9. Japanese.

PMID:
10783572
20.

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J.

Neurology. 2001 Dec 11;57(11):2089-94.

PMID:
11739831
Items per page

Supplemental Content

Write to the Help Desk